Business Context and Reporting Period
This Form 6-K filing by Tiziana Life Sciences Ltd. is dated March 2, 2022. The report addresses a regulatory notice received on February 22, 2022, regarding the company's continued listing status on the Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a stock price deficiency notice.
Material Changes and Listing Status
The company received a deficiency letter from Nasdaq stating that its common shares closed below the $1.00 minimum bid price for 30 consecutive business days. This triggers a compliance period under Nasdaq Listing Rule 5810(c)(3)(A).
- Deficiency: Bid price below $1.00 per share for 30 consecutive days.
- Compliance Period: 180 calendar days to regain compliance, expiring August 22, 2022.
- Requirement: The closing bid price must be at least $1.00 per share for a minimum of 10 consecutive trading days during the compliance period.
Outlook, Risks, and Management Commentary
Management intends to actively monitor the closing bid price and is evaluating options to regain compliance. The filing explicitly states there can be no assurance that the company will regain compliance or remain listed.
- Delisting Risk: Failure to comply within the initial 180 days may lead to delisting unless the company qualifies for an additional 180-day period by meeting other listing standards (e.g., market value of publicly held shares).
- Appeal Rights: If delisting is determined, the company may appeal to a Hearings Panel.
Investor Verification Checklist
- Verify the current closing bid price of Tiziana Life Sciences Ltd. common shares to assess progress toward the $1.00 threshold.
- Monitor for any subsequent announcements regarding a reverse stock split or other capital actions intended to restore compliance.
- Check the company's market value of publicly held shares to determine eligibility for a second compliance period if the first expires without success.
- Review the company's cash position in other filings to assess its ability to fund operations while addressing the listing deficiency.